Drug General Information (ID: DDI8ZPKUM7)
Drug Name			Basiliximab		Drug Info		Canakinumab		Drug Info
Drug Type		Monoclonal antibody				Monoclonal antibody
Therapeutic Class		Immunomodulatory Agents				Interleukin Inhibitors

Mechanism of Basiliximab-Canakinumab Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Basiliximab				Canakinumab
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Basiliximab and Canakinumab

Recommended Action
Management		The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.

References
1	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
2	Product Information. Ilaris (canakinumab). Novartis Pharmaceuticals, East Hanover, NJ.
3	Product Information. Kineret (anakinra). Amgen, Thousand Oaks, CA.